Skip to Main Content

Advertisement

Skip Nav Destination

Issues

In This Issue

In the Spotlight

Review

Research Brief

Associations between axi-cel product features, apheresis attributes, pharmacokinetics, pharmacodynamics, and clinical outcomes were uncovered in ZUMA-7, the largest clinical trial for CAR T-cell therapy in second-line LBCL.

Research Articles

Transcriptional regulation of IRF4-MYC feed-forward super-enhancer is the key to IMiD antimyeloma activity, rational therapy combinations, and mechanisms of resistance.

In myeloma cells resistant to IMiD and Cereblon E3 ligase modulators, increased ETV4 at myeloma enhancers compensates for IKZF1 and IKZF3 degradation by CUL4a-Cereblon.

Retraction

Acknowledgment to Reviewers

Close Modal

or Create an Account

Close Modal
Close Modal